Psoriasis Drugs Market to Cross US$ 21 Billion by 2031 - Persistence Market Research

✅ Market Overview and Growth Insights

The global psoriasis drugs market was valued at approximately US$ 11.37 billion in 2021 and is forecasted to reach US$ 21.48 billion by 2031, expanding at a healthy CAGR of 6.5% during the forecast period. Psoriasis, an autoimmune condition that leads to chronic inflammation and skin lesions, affects more than 125 million people globally, driving strong demand for effective treatment options.

One of the key drivers of this growth is the rising adoption of systemic treatments and biologics, which offer more targeted relief with fewer side effects. Increasing awareness among patients and improved access to healthcare-particularly in emerging economies-are also fueling demand. Among the various segments, topical psoriasis drugs dominated the market in 2021, capturing a 41.7% market share, due to their ease of use and affordability. Meanwhile, North America, led by the U.S., remains the largest regional market, accounting for 88.7% of North America's market share. This dominance is attributed to well-established healthcare infrastructure, high prevalence rates, and active R&D investments from pharmaceutical giants.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/25102

Furthermore, companies are focusing on novel biologic developments and combination therapies to enhance treatment efficacy. Ongoing clinical trials, favorable regulatory frameworks, and increasing diagnosis rates all contribute to the projected market expansion through 2031.

✅ Key Highlights from the Psoriasis Drugs Market Report

➤ Global psoriasis drugs market reached US$ 11.37 Bn in 2021 and is projected to grow at a CAGR of 6.5%.
➤ Topical psoriasis drugs accounted for the largest market share at 41.7% in 2021.
➤ North America holds the leading regional share, driven by the U.S. at 88.7% in 2021.
➤ Corticosteroids continue to be the most widely adopted drug class, with a growing market share.
➤ China is emerging as a lucrative market with a forecast CAGR of 9.4%.
➤ Biologics are expected to carry market growth forward through innovation and fewer side effects.

✅ Market Segmentation: Product Types and Drug Classes

The psoriasis drugs market is segmented by product type, drug class, and distribution channel. By product type, the market is categorized into topical, oral, and injectable drugs. Topical drugs remain the most widely used, especially for mild to moderate cases, due to their direct application and minimal systemic side effects. This category accounted for over 41% of the total market in 2021 and is forecasted to grow at a CAGR of 6.3% through 2031.

Injectable and oral drugs are predominantly used in moderate to severe cases, particularly systemic treatments such as biologics and methotrexate. Injectable biologics like TNF inhibitors and interleukin inhibitors are increasingly preferred due to their long-term efficacy, especially in plaque psoriasis and psoriatic arthritis. Oral drugs offer convenience and rapid relief, but concerns about side effects often necessitate physician monitoring.

In terms of drug classes, corticosteroids led the market in 2021 with a 34.9% share and are expected to rise to 37.1% by 2031. Their broad-spectrum anti-inflammatory properties and effectiveness in flare-up control make them the first line of defense in clinical practice. Interleukin inhibitors and TNF inhibitors are gaining traction in biologics, supported by their strong clinical performance and minimal adverse effects, particularly in patients who do not respond to conventional treatments.

✅ Regional Insights: Key Markets and Emerging Economies

North America dominates the global psoriasis drugs market, primarily due to the U.S., which held 88.7% of the regional share in 2021. The market here is bolstered by the high prevalence of psoriasis, favorable reimbursement policies, and the strong presence of pharmaceutical leaders. Robust healthcare infrastructure, extensive clinical research, and consumer awareness further solidify the region's leading position.

In Europe, the U.K. is a frontrunner with an expected CAGR of 7.1% over the forecast period. The region benefits from high clinical trial activity, government support for dermatological health, and fast-tracked approvals for biologics. The approval of Bimekizumab, for instance, exemplifies Europe's proactive approach to adopting innovative treatments.

Meanwhile, China is emerging as a high-potential market with a projected CAGR of 9.4%. Rapid urbanization, increased healthcare spending, and growing awareness of skin disorders have led to better diagnosis rates and access to advanced treatment. With companies like Novartis launching products such as Cosentyx®, the Chinese market is becoming a hotbed for international investment and pharmaceutical innovation.

✅ Market Drivers

The demand for psoriasis drugs is primarily driven by the increasing prevalence of psoriasis worldwide and the associated comorbidities such as psoriatic arthritis and mental health disorders. As these health complications become better understood, there is a growing emphasis on early and long-term treatment. Another significant driver is the rise in combination therapy approaches, which allow for better disease management and patient outcomes.

Additionally, continuous innovation in biologic therapies is revolutionizing treatment protocols. Novel drugs that target specific immune responses, such as interleukin inhibitors, are increasingly adopted due to their long-term benefits and reduced side-effect profiles. R&D investments, particularly in personalized medicine and gene-based therapies, also provide tailwinds for the market.

✅ Market Restraints

Despite optimistic growth, the psoriasis drugs market faces some notable challenges. High treatment costs, particularly for biologics and combination therapies, pose a major barrier, especially in low and middle-income countries. These drugs often require long-term administration, significantly increasing healthcare expenditures.

Additionally, lack of awareness and underdiagnosis of the condition in several regions limit the market's full potential. Cultural stigmas and limited access to dermatological services in rural or underserved communities often result in delayed or improper treatment. Regulatory hurdles and the time-consuming nature of clinical trials further slow down the introduction of new therapies.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/25102

✅ Market Opportunities

Significant opportunities lie in the development of novel biologics targeting new immune pathways. Pharmaceutical companies are actively pursuing advanced formulations and biotech-based therapies that provide long-term symptom control with fewer doses and less toxicity. These innovations aim to replace conventional drugs and attract patients who are resistant to current treatments.

Another promising area is digital health integration. Telemedicine and AI-based skin diagnosis tools can help identify early signs of psoriasis and ensure timely intervention. Moreover, expansion in emerging markets like China, India, and Brazil, where awareness and healthcare access are rising, offers vast untapped potential. Regulatory approvals and investments in local manufacturing units can pave the way for rapid market penetration.

✅ Frequently Asked Questions (FAQs)

➤ How Big is the Psoriasis Drugs Market Globally?
➤ Who are the Key Players in the Global Psoriasis Drugs Market?
➤ What is the Projected Growth Rate of the Psoriasis Drugs Market?
➤ What is the Market Forecast for Psoriasis Drugs for 2032?
➤ Which Region is Estimated to Dominate the Psoriasis Drugs Industry through the Forecast Period?

✅ Company Insights: Key Market Players

✦ Janssen Biotech, Inc.
✦ Novartis International Ltd.
✦ Amgen Inc.
✦ Pfizer Inc.
✦ Takeda Pharmaceutical Company Ltd.
✦ Merck & Co, Inc.
✦ AbbVie Inc.
✦ Eli Lilly and Company
✦ Boehringer Ingelheim GmbH
✦ Sun Pharmaceutical Industries Ltd.

✅ Recent Market Developments

■ In February 2021, Amgen submitted a supplemental New Drug Application (sNDA) to the FDA for Otezla® for treating mild-to-moderate plaque psoriasis.
■ In April 2021, AbbVie filed for FDA and EMA approval of SKYRIZI® (risankizumab) to treat adults with active psoriatic arthritis.

✅ Reasons to Buy the Report

Gain an in-depth understanding of key market trends and dynamics.

Identify the fastest-growing segments and regions in the psoriasis drugs market.

Access comprehensive data on leading market players and their strategies.

Understand current and emerging regulatory scenarios impacting the market.

Make informed business decisions based on market forecasts through 2031.

Evaluate the market impact of COVID-19 and expected recovery timelines.

✅ Conclusion

Despite challenges like high treatment costs and limited awareness in underdeveloped regions, the market continues to witness strong support from regulatory bodies, ongoing R&D investments, and a shift toward personalized medicine. Topical and corticosteroid therapies remain dominant, while biologics are quickly emerging as transformative long-term solutions for moderate to severe cases. As the demand for safer, more effective, and easily accessible treatments rises, companies with robust pipelines, strategic collaborations, and patient-first innovation strategies will be best positioned to lead the next phase of growth in the global psoriasis drugs industry.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.